Tilray Brands, Inc. (TLRY) Stock Slides as Market Rises: Facts to Know Before You Trade

Tilray Brands (TLRY) recently closed down 6.34% despite a broader market rally, though its shares have surged 105.84% over the past month, significantly outperforming market benchmarks. The company is set to report earnings on July 28, 2025, with consensus estimates projecting a quarterly EPS of -$0.03 (up 25% YoY) on $240.05 million in revenue (up 4.42% YoY). However, full-year EPS is forecast at -$1.01, a substantial decline from the prior year, while revenue is expected to be flat at $838.75 million. TLRY currently holds a Zacks Rank of #3 (Hold) within an industry ranked in the bottom 30%, suggesting a cautious outlook despite recent stock momentum.

Analysis

Tilray Brands, Inc. (TLRY) exhibits a significant disconnect between its recent stock momentum and its underlying fundamental forecasts. The stock's single-day decline of 6.34% against a rising market contrasts sharply with its explosive 105.84% gain over the past month, signaling high volatility and potential profit-taking. While upcoming quarterly estimates for July 2025 suggest near-term improvement with a projected 4.42% revenue increase and a 25% year-over-year improvement in EPS to -$0.03, the full-year outlook is substantially weaker. Consensus estimates project full-year revenue to be flat and a severe earnings deterioration, with EPS forecasted at -$1.01, a -206.06% decline from the prior year. This fundamental weakness is compounded by its placement in the 'Medical - Products' industry, which ranks in the bottom 30% of over 250 industries tracked by Zacks. The neutral Zacks Rank of #3 (Hold) and a steady consensus EPS estimate suggest analysts are cautious, weighing the positive short-term earnings trajectory against the deeply negative full-year projections and industry headwinds.

Key Decisions for Investors

• Given the extreme volatility, with a 105.84% monthly gain followed by a sharp daily pullback, investors should consider if recent price action has outpaced fundamentals and review risk exposure accordingly.
• Focus intently on the upcoming July 28 earnings release for management's full-year guidance, as the key risk is the forecasted -206.06% annual EPS decline and flat revenue, which contradicts the expected quarterly improvement.
• A cautious stance is warranted due to the stock's #3 (Hold) rating and its operation within an industry ranked in the bottom 30%, suggesting significant headwinds to sustained performance until a clearer path to annual profitability is established.